The World of Health & Medicine News

Mayo Clinic’s AI tool identifies 9 dementia types, including Alzheimer’s, with one scan 

Mayo Clinic’s AI tool identifies 9 dementia types, including Alzheimer’s, with one scan 

 Mayo Clinic researchers have developed a new artificial intelligence (AI) tool that helps clinicians identify brain activity patterns linked to nine types of dementia, including Alzheimer’s disease, using a single, widely available scan — a transformative advance in early, accurate diagnosis.

The tool, StateViewer, helped researchers identify the dementia type in 88% of cases, according to research published online on June 27, 2025, in Neurology, the medical journal of the American Academy of Neurology. It also enabled clinicians to interpret brain scans nearly twice as fast and with up to three times greater accuracy than standard workflows. Researchers trained and tested the AI on more than 3,600 scans, including images from patients with dementia and people without cognitive impairment.

his innovation addresses a core challenge in dementia care: identifying the disease early and precisely, even when multiple conditions are present. As new treatments emerge, timely diagnosis helps match patients with the most appropriate care when it can have the greatest impact. The tool could bring advanced diagnostic support to clinics that lack neurology expertise.

The rising toll of dementia

Dementia affects more than 55 million people worldwide, with nearly 10 million new cases each year. Alzheimer’s disease, the most common form, is now the fifth-leading cause of death globally. Diagnosing dementia typically requires cognitive tests, blood draws, imaging, clinical interviews and specialist referrals. Even with extensive testing, distinguishing conditions such as Alzheimer’s, Lewy body dementia and frontotemporal dementia remains challenging, including for highly experienced specialists.

StateViewer was developed under the direction of David Jones, M.D., a Mayo Clinic neurologist and director of the Mayo Clinic Neurology Artificial Intelligence Program.

“Every patient who walks into my clinic carries a unique story shaped by the brain’s complexity,” Dr. Jones says. “That complexity drew me to neurology and continues to drive my commitment to clearer answers. StateViewer reflects that commitment — a step toward earlier understanding, more precise treatment and, one day, changing the course of these diseases.”

To bring that vision to life, Dr. Jones worked alongside Leland Barnard, Ph.D., a data scientist who leads the AI engineering behind StateViewer.

“As we were designing StateViewer, we never lost sight of the fact that behind every data point and brain scan was a person facing a difficult diagnosis and urgent questions,” Dr. Barnard says. “Seeing how this tool could assist physicians with real-time, precise insights and guidance highlights the potential of machine learning for clinical medicine.”

Turning brain patterns into clinical insight 

The tool analyzes a fluorodeoxyglucose positron emission tomography (FDG-PET) scan, which shows how the brain uses glucose for energy. It then compares the scan to a large database of scans from people with confirmed dementia diagnoses and identifies patterns that match specific types, or combinations, of dementia.

Alzheimer’s typically affects memory and processing regions, Lewy body dementia involves areas tied to attention and movement, and frontotemporal dementia alters regions responsible for language and behavior. StateViewer displays these patterns through color-coded brain maps that highlight key areas of brain activity, giving all clinicians, even those without neurology training, a visual explanation of what the AI sees and how it supports the diagnosis.

Mayo Clinic researchers plan to expand the tool’s use and will continue evaluating its performance in a variety of clinical settings.

spot_img

Explore more

spot_img

Exclusive: Indonesia will give food companies two years to meet new...

Exclusive: Indonesia will give food companies two years to meet new labelling rules  Indonesia will set a deadline of two years for food and beverage...

BioXcel to seek approval for at-home use of agitation drug after...

BioXcel to seek approval for at-home use of agitation drug after upbeat study BioXcel Therapeutics (BTAI.O), opens new tab said on Wednesday it plans to seek...

US FDA approves updated COVID shots for all people 65 and...

US FDA approves updated COVID shots for all people 65 and older and those at high risk  The U.S. Food and Drug Administration has approved...

Lilly pill cuts body weight by 10.5% in patients with type...

Lilly pill cuts body weight by 10.5% in patients with type 2 diabetes  Eli Lilly (LLY.N), opens new tab said on Tuesday its experimental GLP-1 pill helped...

Eli Lilly temporarily halts UK shipments of weight-loss drug Mounjaro

Eli Lilly temporarily halts UK shipments of weight-loss drug Mounjaro  Eli Lilly (LLY.N), opens new tab has temporarily paused shipments of its weight-loss drug Mounjaro in the...

British regulator approves GSK’s Blujepa drug for UTI in women and...

British regulator approves GSK's Blujepa drug for UTI in women and girls Britain's medicines regulator said on Thursday it approved GSK's (GSK.L), opens new tab Blujepa,...

Simple ways to improve mental health

Simple ways to improve mental health Sometimes you need a mental lift. There are some simple steps you can take to build a “happiness habit”...

SFDA Approves Registration of “Tzield” for Delaying Type 1 Diabetes

SFDA Approves Registration of “Tzield” for Delaying Type 1 Diabetes The Saudi Food and Drug Authority (SFDA) has approved the registration of Tzield (teplizumab) to...